• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nuvectis Pharma Inc.

    1/3/25 5:00:54 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    S-8 1 tm251759d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on January 3, 2025

    File No. 333-     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    NUVECTIS PHARMA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   86-2405608
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)

     

    1 Bridge Plaza Suite 275

    Fort Lee, NJ 07024

    (Address, including Zip Code, of Principal Executive Offices)

     

    Amended and Restated Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021)

    (Full title of the plan)

     

      Copy to:

    Ron Bentsur

    Chairman, Chief Executive Officer and President

    Nuvectis Pharma, Inc.
    Bridge Plaza Suite 275

    Fort Lee, NJ 07024

    (201) 614-3151

    (Name, address and telephone number of agent for service)

    Matthew W. Mamak, Esq.

    Alston & Bird LLP

    90 Park Avenue, 14th Floor
    New York, New York 10016

    (212) 210-1256

     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer o Accelerated filer o
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Nuvectis Pharma, Inc. (the “Company”) has filed this Registration Statement on Form S-8 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), to register (i) 559,227 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), that may be issued under the Nuvectis Pharma, Inc. Amended and Restated Global Incentive Plan (2021) (the “Plan”); and (ii) such additional shares that may become issuable in accordance with the adjustment and anti-dilution provisions of the Plan. These shares were automatically added to the Plan effective as of January 1, 2025, pursuant to the evergreen share reserve provision contained in the Plan.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

      

    (a)        The documents constituting Part I of this registration statement on Form S-8 (this “Registration Statement”) will be delivered to participants in the Plan as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    (b)       Upon written or oral request, the Company will provide, without charge, the documents incorporated by reference in Item 3 of Part II of this Registration Statement. The documents are incorporated by reference in the Section 10(a) prospectus. The Company will also provide, without charge, upon written or oral request, other documents required to be delivered to participants pursuant to Rule 428(b). Requests for the above-mentioned information should be directed to our corporate headquarters at the following address: 1 Bridge Plaza, Suite 275, Fort Lee, NJ 07024, Attn: Ron Bentsur, or by calling (201) 614-3151.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents, filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference and deemed to be a part hereof (excluding any portions of such documents that are deemed to be “furnished” but not “filed” for purposes of the Exchange Act):

     

    (a)The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on March 5, 2024;

     

    (b)The Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, filed on May 7, 2024; June 30, 2024, filed on August 6, 2024; and September 30, 2024, filed on November 5, 2024;

     

    (c)The Company’s Current Reports on Form 8-K, filed with the Commission on June 13, 2024, and August 29, 2024;

     

    (d)The description of the Company’s Common Stock contained in Exhibit 4.6 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and any amendment or report filed with the Commission for the purpose of updating such description;

     

    (e)All reports filed by the Company pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since December 31, 2023 (excluding any portions of such documents that are deemed to be “furnished” but not “filed” for purposes of the Exchange Act); and

     

    (f)All other documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities that remain unsold.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4.Description of Securities.

     

    Not applicable.

     

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.Indemnification of Directors and Officers.

     

    Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its officers or directors to the company or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper benefit. Our certificate of incorporation provides that no officer or director shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as an officer or director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of officers or directors for breaches of fiduciary duty as described in the previous sentence.

     

    Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is party or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Our certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), liabilities, losses, judgments, fines, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

     

    Our certificate of incorporation also provides that we will indemnify any Indemnitee who was or is a party to any threatened, pending or completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If we don’t assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.

     

     

     

     

    We maintain a general liability insurance policy which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8.Exhibits.

     

    See the Exhibit Index, which is incorporated herein by reference.

     

    Item 9.Undertakings.

     

    (a)       The Company hereby undertakes:

     

    (1)        To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)       To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii)      To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;

     

    (iii)     To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    Provided, however, That

     

    (A)Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if this Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in this Registration Statement;

     

    (2)       That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

    (3)      To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)      The undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Company’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h)      Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    The Registrant. Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fort Lee, State of New Jersey, on this 3rd day of January, 2025.

     

      NUVECTIS PHARMA, INC.
       
      By: /s/ Ron Bentsur
        Ron Bentsur
        Chairman, Chief Executive Officer and President

     

     

    POWER OF ATTORNEY

     

    We, the undersigned directors and/or executive officers of Nuvectis Pharma, Inc., hereby severally constitute and appoint Ron Bentsur, acting singly, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and his name, for him in any and all capacities, to sign this report and to file the same, with all exhibits thereto and other documents in connection therewith, and to sign any or all amendments (including pre-effective and post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, including any Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or any of his substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Ron Bentsur   Chairman, Chief Executive Officer and President   January 3, 2025
    Ron Bentsur   (Principal Executive Officer)    
             
    /s/ Michael J. Carson   Vice President of Finance   January 3, 2025
    Michael J. Carson   (Principal Financial and Accounting Officer)    
             
    /s/ Kenneth Hoberman   Director   January 3, 2025
    Kenneth Hoberman        
             
    /s/ Matthew L. Kapan   Director   January 3, 2025
    Matthew L. Kapan        
             
    /s/ James F. Oliviero III   Director   January 3, 2025
    James F. Oliviero III        

     

     

     

     

    EXHIBIT INDEX
    TO
    REGISTRATION STATEMENT ON FORM S-8

     

    Exhibit Number   Description
    4.1   Second Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc., filed as Exhibit 3.1 to the Form 8-K filed on February 4, 2022 and incorporated herein by reference.
         
    4.2   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc., filed as Exhibit 3.3 to the Form 8-K filed on February 4, 2022 and incorporated herein by reference.
         
    4.3   Amended and Restated Bylaws of Nuvectis Pharma, Inc., filed as Exhibit 3.2 to the Form 8-K filed on February 4, 2022 and incorporated herein by reference.
         
    5.1   Opinion of Alston & Bird LLP.
         
    23.1   Consent of Kesselman & Kesselman.
         
    23.2   Consent of Alston & Bird LLP (included in Exhibit 5.1).
         
    24.1   Power of Attorney (included on signature page).
         
    99.1   Amended and Restated Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) filed with the Definitive Proxy Statement on April 28, 2023, and incorporated herein by reference.
         
    107   Filing fee table.

     

     

     

     

    Get the next $NVCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    1/9/26 4:32:18 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    1/9/26 4:31:39 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    1/9/26 4:30:55 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    SEC Filings

    View All

    Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    11/4/25 8:16:48 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nuvectis Pharma Inc.

    10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

    11/4/25 8:01:41 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    9/25/25 8:23:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

    Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a

    12/17/25 7:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

    Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company")), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Unc

    11/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

    FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ:NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dos

    11/4/25 8:15:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Bentsur Ron bought $28,600 worth of shares (5,000 units at $5.72), increasing direct ownership by 0.14% to 3,525,924 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:01:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sanchez Juan bought $75,270 worth of shares (13,000 units at $5.79), increasing direct ownership by 20% to 78,150 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:38 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaplan Matthew L. bought $64,240 worth of shares (11,000 units at $5.84), increasing direct ownership by 10% to 124,760 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:15 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Nuvectis Pharma with a new price target

    Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

    4/2/25 8:05:05 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Nuvectis Pharma with a new price target

    Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

    3/17/25 7:40:44 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

    Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

    7/13/22 8:35:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    11/5/24 10:55:09 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/28/24 8:37:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nuvectis Pharma Inc.

    SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/6/24 8:47:33 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Financials

    Live finance-specific insights

    View All

    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

    The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

    8/11/25 4:30:00 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care